Gastrointestinal stromal tumour | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The stomach or small intestine are the typical sites for the development of gastrointestinal stromal tumors (GIST), which are intestinal tumors. It is believed that the source of this type of tumor as well as its precursors are interstitial cells of Cajal (ICCs), specialized cells found in the gastrointestinal system. Complete surgical excision with the goal of R0 excision (i.e., at the very least, an excision with margins free of tumor cells at the site of origin in the GI tract). R1 (microscopically positive) margins may be acceptable for low-risk GISTs in unfavorable sites when decisions are made in collaboration with the patient.

Description

Gastrointestinal stromal tumors (GISTs), which are intestinal tumors, typically form in the stomach or small intestine. It is believed that the source of this type of tumor as well as its precursors are interstitial cells of Cajal (ICCs), specialized cells found in the gastrointestinal system. Affected people may develop one or more tumors. GISTs are typically prevalent in people between the ages of 40 and 70; children and young adults rarely develop them. The symptoms of small tumors may be completely absent. However, in addition to discomfort or swelling in the abdomen, some GIST patients may also experience nausea, vomiting, loss of appetite, or weight loss. Anaemia (low red blood cell counts), which can make a patient feel weak and exhausted, can occasionally be brought on by tumors. While stomach or throat bleeding may cause blood vomiting, intestinal bleeding can produce dark, tarry feces. A sporadic GIST is a single tumor that affects people who do not have a family history of GIST. People with familial GISTs frequently have multiple tumors in addition to other signs or symptoms like dark skin patches on various body parts and non-cancerous enlargement (hyperplasia) of other cells in the gastrointestinal system.

Gastrointestinal stromal tumour (Epidemiology)

GISTs can develop at any age, but the majority of cases are discovered much later in life, with a median age of diagnosis in the 60s. An annual incidence rate of 6 to 14 per 10,000 people and an age-adjusted incidence rate of 0 to 8 per 10,000 people are reported by population-based studies from European nations as well as SEER (surveillance, epidemiology, and end results) data from the United States. Due to the relative homogeneity of prior population-based studies, the global incidence of GISTs is unfortunately unknown. GISTs affect both men and women about equally, according to sex.

Gastrointestinal stromal tumour -Current Market Size & Forecast Trends

The market for gastrointestinal stromal tumors (GISTs) is expected to grow significantly, with an estimated value of USD 1.18 billion in 2023, projected to reach approximately USD 1.69 billion by 2028, reflecting a compound annual growth rate (CAGR) of 7.1%. This growth is driven by factors such as increased awareness and early diagnosis, the emergence of targeted therapies like imatinib and sunitinib, and advancements in surgical techniques and personalized medicine. The market is characterized by a rising focus on patient-centric healthcare and the integration of precision medicine into clinical practice. North America is anticipated to dominate the market due to its advanced healthcare infrastructure, while the Asia-Pacific region is expected to be the fastest-growing area, supported by improving access to treatments and ongoing research initiatives. Overall, the gastrointestinal stromal tumor market is well-positioned for continued expansion through 2035, driven by ongoing research and development efforts in this field.

Complete surgical excision with the goal of R0 excision (i.e. at the very least, an excision with margins free of tumor cells at the site of origin in the GI tract). R1 (microscopically positive) margins may be acceptable for low-risk GISTs in unfavorable locations if the decision is made in collaboration with the patient. Patients with a high risk of relapse should receive adjuvant therapy with imatinib 400 mg/day for three years. If there is a KIT exon 9 mutation, adjuvant imatinib at a higher dose of 800 mg every day for three years may be considered. Adjuvant therapy is not recommended for GISTs that have the D842V mutation in PDGFRA exon 18. If R0 surgery is impossible or would have detrimental side effects and the tumor carries a sensitive mutation, preoperative imatinib therapy is standard. When the PDGFRA-D842V mutation is present, avapritinib as a neoadjuvant therapy may be considered. Imatinib is the preferred first-line therapy for patients with locally advanced, inoperable, and metastatic lesions, with the exception of GIST without KIT/PDGFRA mutations or with a PDGFRA exon 18 D842V mutation. Imatinib is the suggested course of treatment if the tumor has a sensitive genotype, and the patient has metastatic disease after having all lesions surgically removed.

Report Highlights

Gastrointestinal stromal tumour - Current Market Trends

Gastrointestinal stromal tumour - Current & Forecasted Cases across the G8 Countries

Gastrointestinal stromal tumour - Market Opportunities and Sales Potential for Agents

Gastrointestinal stromal tumour - Patient-based Market Forecast to 2035

Gastrointestinal stromal tumour - Untapped Business Opportunities

Gastrointestinal stromal tumour - Product Positioning Vis-a-vis Competitors' Products

Gastrointestinal stromal tumour - KOLs Insight